PCSK9: Its Role in Lipid Metabolism and as a Novel Target for the Treatment of Metabolic Kidney Disease
PCSK9 inhibitors show promise in metabolic kidney diseases, but large-scale trials are needed to clarify their long-term efficacy and optimal application scope.
Authors
- Qi Ling (ORCID: https://orcid.org/0000-0002-7377-2381)
- Santao Ou (ORCID: https://orcid.org/0000-0003-4149-1996)
- Weihua Wu (ORCID: https://orcid.org/0000-0002-1880-8089)
- Dongmei Zhang (ORCID: https://orcid.org/0000-0002-8771-8255)
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
Publication Details
- Journal
- Current Vascular Pharmacology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.2174/0115701611392964250918094721
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01